G6PC3 and disorder of glycogen metabolism: Consequently, G6PC3-deficient patients appear to need significantly lower daily doses of EMPA (0.1–0.2 mg/kg/day) compared with GSD-1b patients to achieve similar 1,5-AG excretion (16).